Commercial Momentum Syndax is a commercial-stage company with ongoing product launches (Revuforj and Niktimvo) and rising near-term revenue, signaling appetite for partnerships to scale commercialization, including co-promotion, regional licensing, and payer-market access collaborations.

Pipeline Opportunities A diversified pipeline featuring a menin inhibitor for relapsed/refractory AML and an anti–CSF-1R monoclonal antibody for chronic graft-versus-host disease presents multiple licensing, co-development, and strategic collaboration opportunities across indications and geographies.

Market Access To accelerate adoption, Syndax will benefit from market access and payer strategy partnerships, distribution deals, and patient support programs, especially in the US and potential international markets.

Financial Flexibility With solid revenue and a significant funding runway, Syndax appears positioned for milestone-based partnerships, licensing deals, or co-development financings to advance the late-stage pipeline and expand commercial reach.

BD Readiness Active engagement in investor events and conferences (R&D Day, JPM Healthcare, Guggenheim Summit, ASH) indicates openness to BD discussions; prioritize outreach at upcoming forums and propose structured deal frameworks.